+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

5-Hydroxytryptamine Receptor 7 - Drugs In Development, 2021

  • ID: 5359587
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 85 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Adamed Sp zoo
  • Celon Pharma SA
  • Core One Labs Inc
  • Daya Drug Discoveries Inc
  • H. Lundbeck AS
  • Johnson & Johnson
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

According to the recently published report '5-Hydroxytryptamine Receptor 7 - Drugs In Development, 2021'; 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - 5-HT7 receptor is a member of the GPCR superfamily and it is activated by the serotonin (5-HT). The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It plays an important role in autistic disorder and other neuropsychiatric disorders.

The report '5-Hydroxytryptamine Receptor 7 - Drugs In Development, 2021' outlays comprehensive information on the 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 5 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal and Respiratory which include indications Bipolar Disorder (Manic Depression), Schizophrenia, Anxiety Disorders, Autism, Depression, Neuropathic Pain (Neuralgia), Psychiatric Disorders, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Crohn's Disease (Regional Enteritis), Dementia Associated With Alzheimer's Disease, Generalized Anxiety Disorder (GAD), Idiopathic Pulmonary Fibrosis, Inflammatory Pain, Major Depressive Disorder, Parkinson's Disease, Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder, Sleep Disorders and Ulcerative Colitis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
  • The report reviews 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Adamed Sp zoo
  • Celon Pharma SA
  • Core One Labs Inc
  • Daya Drug Discoveries Inc
  • H. Lundbeck AS
  • Johnson & Johnson
  • MORE
Introduction
  • Report Coverage
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Overview

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Companies Involved in Therapeutics Development
  • Adamed Sp zoo
  • Avineuro Pharmaceuticals Inc
  • Celon Pharma SA
  • Core One Labs Inc
  • Daya Drug Discoveries Inc
  • H. Lundbeck AS
  • Johnson & Johnson
  • LB Pharmaceuticals Inc
  • Praeventix LLC
  • Reviva Pharmaceuticals Inc
  • Sumitomo Dainippon Pharma Co Ltd
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Drug Profiles

ADN-1184 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ADN-3662 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
AVN-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
brilaroxazine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
DDD-028 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
dimethyl tryptamine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
JNJ-18038683 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
LB-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
LB-102 LA - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
LB-104 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
lurasidone hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Agonize 5-HT7 for Neuropathic Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Antagonize 5 HT7 Receptors for Crohn’s Disease and Ulcerative Colitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Target 5-HT7R for Sleep Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
vortioxetine hydrobromide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Dormant Products

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Discontinued Products

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Product Development Milestones

Featured News & Press Releases
  • May 03, 2021: H. Lundbeck: New study finds that vortioxetine helps patients with MDD and comorbid Generalized Anxiety Disorder
  • May 03, 2021: Sunovion presents data from marketed and late-stage development psychiatric compounds at the American Psychiatric Association (APA) Annual Meeting 2021
  • Apr 26, 2021: Reviva announces full details of positive phase 2 clinical trial results for acute Schizophrenia
  • Apr 22, 2021: Vortioxetine significantly improves overall functioning in a global real-world study in Major Depressive Disorder
  • Feb 02, 2021: LB Pharmaceuticals announces the initiation of patient dosing in open label phase 1b imaging study of LB-102
  • Sep 17, 2020: Lundbeck presents positive data from the COMPLETE study with vortioxetine
  • Sep 14, 2020: LB Pharmaceuticals announces results of LB-102 phase 1 first-in-human clinical study
  • Sep 02, 2020: LB Pharmaceuticals announces the Hiring of Dr. Anna Eramo as Chief Medical Officer
  • Jul 23, 2020: CHMP recommended extensions of indication for Latuda
  • Jun 06, 2020: Celon Pharma signs an agreement with the National Centre for Research and Development (NCRD) for subsidising the Company’s subsequent projects
  • Mar 25, 2020: Sumitomo Dainippon Pharma announces approval of atypical antipsychotic agent, LATUDA tablets in Japan
  • Jan 23, 2020: LB Pharmaceuticals starts dosing of schizophrenia drug
  • Oct 09, 2019: ChemRar Group of Companies announces the successful completion of the second phase of clinical trials of an innovative drug for the treatment of generalized anxiety disorder
  • Sep 20, 2019: Takeda and Lundbeck’s Trintellix approved in Japan for depression
  • Sep 03, 2019: Sumitomo Dainippon Pharma Announces the Launch of Atypical Antipsychotic LATUDA in China
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Adamed Sp zoo, 2021
  • Pipeline by Avineuro Pharmaceuticals Inc, 2021
  • Pipeline by Celon Pharma SA, 2021
  • Pipeline by Core One Labs Inc, 2021
  • Pipeline by Daya Drug Discoveries Inc, 2021
  • Pipeline by H. Lundbeck AS, 2021
  • Pipeline by Johnson & Johnson, 2021
  • Pipeline by LB Pharmaceuticals Inc, 2021
  • Pipeline by Praeventix LLC, 2021
  • Pipeline by Reviva Pharmaceuticals Inc, 2021
  • Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2021
  • Dormant Products, 2021
  • Discontinued Products, 2021
List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
Note: Product cover images may vary from those shown
  • Adamed Sp zoo
  • Avineuro Pharmaceuticals Inc
  • Celon Pharma SA
  • Core One Labs Inc
  • Daya Drug Discoveries Inc
  • H. Lundbeck AS
  • Johnson & Johnson
  • LB Pharmaceuticals Inc
  • Praeventix LLC
  • Reviva Pharmaceuticals Inc
  • Sumitomo Dainippon Pharma Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll